MichaelThomasMcHaleMD

Obstetrics & Gynecology • La Jolla, CA

Gynecologic Oncology

Clinical Professor, Department of Obstetrics & Gynecology Division Director, Gynecologic Oncology UCSD Moores Cancer Center

Join to view full profile

Dr. McHale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McHale's full profile

Already have an account?

Office
9300 Campus Point Dr
La Jolla, CA 92037
Phone+1 800-926-8273

Fax+1 888-539-8781

Education & Training

University of California (Irvine)Fellowship, Gynecologic Oncology, 1999
National Capital ConsortiumResidency, Obstetrics and Gynecology, 1992 - 1996
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1992

Certifications & Licensure

CA State Medical License 1996 - 2025
MD State Medical License 1994 - 1997
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma Start of enrollment: 2010 Aug 01
Completed
Phase 1
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK Start of enrollment: 2018 Feb 06
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

New Insights in Endometriosis Subtypes and Ovarian Cancer Risk.
Michael T McHale
JAMA. 2024-08-13
2 citations
Intraoperative Multivessel Embolization Reduces Blood Loss and Transfusion Requirements Compared to Internal Iliac Artery Balloon Placement during Cesarean Hysterectom...
Zachary T Berman, Christine E Boone, Dora J Melber, Jerasimos Ballas, Rupal Parikh
Journal of Vascular and Interventional Radiology. 2023-11-01
3 citations
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chem...
Robert W Holloway, Premal Thaker, Alberto A Mendivil, Sarfraz Ahmad, Ahmed N Al-Niaimi
International Journal of Gynecological Cancer. 2023-09-04

Press Mentions

Endometriosis Could Lead to Higher Risk of Ovarian Cancer: StudyJuly 18th, 2024
Endometriosis Linked to Four-Fold Higher Odds for Ovarian CancerJuly 18th, 2024
Risk of Ovarian Cancer Higher in Women with EndometriosisJuly 18th, 2024
Join now to see all